Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment

Objectives In endemic countries with a high level of chloroquine resistance, Plasmodium vivax malaria is associated with high morbidity and mortality. In these areas, the dihydroartemisinin–piperaquine combination resulted in clinical response, a more rapid clearance of parasitaemia, compared to chloroquine therapies, and reduction of recrudescence or reinfection.